Pergolide-induced lung disease in patients with Parkinson's disease.
Kastelik
J A
JA
Academic Department of Medicine, University of Hull, Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire, U.K.
Aziz
I
I
Greenstone
M A
MA
Thompson
R
R
Morice
A H
AH
D003371:Cough / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D011014:Pneumonia / Q000139:chemically induced / Q000000981:diagnostic imaging; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
D018491:Dopamine Agonists; D010479:Pergolide